Among 331 eligible treated patients , median PFS was 7.5 months for bevacizumab alone ( 90 % CI , 5.8 to 10.8 months ) , 7.6 months for bevacizumab plus temsirolimus ( 90 % CI , 6.7 to 9.2 months ) , 9.2 months for bevacizumab plus sorafenib ( 90 % CI , 7.5 to 11.4 months ) , and 7.4 months for sorafenib plus temsirolimus ( 90 % CI , 5.6 to 7.9 months ) .